Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1.
Guzik, K., Zak, K.M., Grudnik, P., Magiera, K., Musielak, B., Torner, R., Skalniak, L., Domling, A., Dubin, G., Holak, T.A.(2017) J Med Chem 60: 5857-5867
- PubMed: 28613862 
- DOI: 10.1021/acs.jmedchem.7b00293
- Primary Citation of Related Structures:  
5N2D, 5N2F - PubMed Abstract: 
Blockade of the PD-1/PD-L1 immune checkpoint pathway with monoclonal antibodies has provided significant advances in cancer treatment. The antibody-based immunotherapies carry a number of disadvantages such as the high cost of the antibodies, their limited half-life, and immunogenicity ...